期刊文献+

依托考昔治疗膝骨关节炎的短期疗效及安全性观察 被引量:9

Short-term therapeutic effect of etoricoxib on knee osteoarthritis and its safety
下载PDF
导出
摘要 目的观察依托考昔治疗膝骨关节炎(OA)的疗效和安全性。方法选择25例膝OA患者,口服依托考昔,60mg,3次/d。分别在0周和第3周末进行疗效和安全性评估,疗效指标包括WOMAC骨关节炎指数评分(包括疼痛、僵硬、日常活动难度三个亚指标)、患者膝痛评分、患者对病情评分和医生对病情评分。治疗后指标改善≥30%为有效。结果经过3周的依托考昔治疗,指标均有明显改善(P<0.01),除僵硬外其他指标改善超过30%的比例均≥68%,其中膝痛指标的改善有效率达80%。5例(20%)发生可能与药物相关的不良反应,主要为胃肠道症状及肿胀,不需调整药物剂量或停药症状可好转。无严重不良事件发生。结论依托考昔对膝OA症状有较好的改善作用,短期使用不良反应轻,依从性好。 Objective To observe the therapeutic effect of etoricoxib on knee osteoarthritis(OA) and its safety.Methods Twenty-five patients with knee OA were treated with oral etoricoxib at the dose of 60mg/d.Its therapeutic effect and safety were assessed at weeks 0 and 3,such as Western Ontario McMaster Universities Osteoarthritis(WOMAC) index score(pain,stiffness,and daily activity difficulty),score of knee pain and disease given by patients,and score of disease given by physicians.The treatment was judged effectively when the improved index was≥30%.Results All the indexes were significantly improved 3 weeks after treatment with etoricoxib(P0.01).The therapeutic effect was≥68% except for stiffness and 80% for knee pain.Adverse reaction,mainly manifested as gastrointestinal symptoms and edema,occurred in 5 patients(20%),which improved without reducing the dose or withdrawal of etoricoxib.No severe adverse events occurred.Conclusion Etoricoxib can improve the symptoms of knee OA with mild adverse reaction and good compliance.
出处 《军医进修学院学报》 CAS 2012年第6期562-564,共3页 Academic Journal of Pla Postgraduate Medical School
关键词 依托考昔 骨关节炎 疗效 安全性 etoricoxib osteoarthritis efficacy safety
  • 相关文献

参考文献9

  • 1韩健,赵志刚.新型非甾体抗炎药依托昔布[J].中国新药杂志,2009,18(9):771-772. 被引量:5
  • 2Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association [ J ] . Arthritis Rheum, 1986, 29 (8) : 1039-1049.
  • 3Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC : a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee [ J ] . J Rheumatol, 1988, 15 (12) : 1833-1840.
  • 4Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks : a double-blind, active-comparator controlled trial [ NCT00242489 ] [ J ] . BMC Museuloskelet Disord, 2005, 6 : 58.
  • 5李胜光,崔鸿雁,郭军华,杨春花,黄烽.洛索洛芬治疗膝骨关节炎的临床评价[J].中国新药杂志,2000,9(12):856-858. 被引量:15
  • 6方华伟,叶俏,杜鹏飞.不同剂量依托考昔治疗急性痛风性关节炎的效果及安全性[J].新医学,2011,42(2):85-88. 被引量:19
  • 7Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis [ J ] . BMJ, 2002, 324 ( 7352 ) : 1488-1492.
  • 8Senna G, Bilo MB, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients [ J ] . Eur Ann Allergy Clin Immunol, 2004, 36 (6): 215-218.
  • 9Matsumoto A, Melian A, Shah A, et al. Etoricoxib versus naproxen in patients with rheumatoid arthritis : a prospective, randomized, comparator-controlled 121-week trial [ J ] . Curr Med Res Opin, 2007, 23 ( 9 ) : 2259-2268.

二级参考文献9

共引文献36

同被引文献68

引证文献9

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部